Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response by Turner, Stephen T et al.
RESEARCH Open Access
Power to identify a genetic predictor of
antihypertensive drug response using different
methods to measure blood pressure response
Stephen T Turner
1*, Gary L Schwartz
1, Arlene B Chapman
3, Amber L Beitelshees
4, John G Gums
5,6,
Rhonda M Cooper-DeHoff
5,7, Eric Boerwinkle
8, Julie A Johnson
5,7 and Kent R Bailey
2
Abstract
Background: To determine whether office, home, ambulatory daytime and nighttime blood pressure (BP)
responses to antihypertensive drug therapy measure the same signal and which method provides greatest power
to identify genetic predictors of BP response.
Methods: We analyzed office, home, ambulatory daytime and nighttime BP responses in hypertensive adults
randomized to atenolol (N = 242) or hydrochlorothiazide (N = 257) in the Pharmacogenomic Evaluation of
Antihypertensive Responses Study. Since different measured BP responses may have different predictors, we tested
the “same signal” model by using linear regression methods to determine whether known predictors of BP
response depend on the method of BP measurement. We estimated signal-to-noise ratios and compared power to
identify a genetic polymorphism predicting BP response measured by each method separately and by weighted
averages of multiple methods.
Results: After adjustment for pretreatment BP level, known predictors of BP response including plasma renin
activity, race, and sex were independent of the method of BP measurement. Signal-to-noise ratios were more than
2-fold greater for home and ambulatory daytime BP responses than for office and ambulatory nighttime BP
responses and up to 11-fold greater for weighted averages of all four methods. Power to identify a genetic
polymorphism predicting BP response was directly related to the signal-to-noise ratio and, therefore, greatest with
the weighted averages.
Conclusion: Since different methods of measuring BP response to antihypertensive drug therapy measure the
same signal, weighted averages of the BP responses measured by multiple methods minimize measurement error
and optimize power to identify genetic predictors of BP response.
Keywords: hypertension, blood pressure monitoring, antihypertensive drug therapy, beta-blocker, thiazide diuretic,
plasma renin activity
Background
Although office blood pressure (BP) measurements
remain the standard-of-care, averages of out-of-office
measurements are more reproducible [1]. Out-of-office
averages have also been reported to be more strongly
correlated with subclinical target organ damage [2,3]
and to better predict future cardiovascular disease
events [4-6] than office measurements. Not surprisingly,
BP responses to antihypertensive drug therapy are more
precisely and accurately determined by out-of-office
than office measurements, which are influenced by
white coat and placebo effects [7,8]. Consequently,
greater use of out-of-office methods of BP measurement
has been advocated for clinical decision-making and
research [1].
More individualized approaches to antihypertensive
drug therapy may become possible if genetic poly-
morphisms are discovered that improve the ability to
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any medium, provided the original work is properly cited.predict inter-individual differences in BP response [9].
Known predictors are limited to race, age, and plasma
renin activity [10,11], which explain less than 50% of
interindividual variation in BP response to single-drug
therapy [12,13]. Most previous studies have attempted
to identify genetic or non-genetic predictors of office BP
response, which is not very reproducible and correlates
only modestly with home and ambulatory BP responses
[7,8,14-16]. Whether out-of-office measurements of BP
response can improve the ability to identify predictors
of BP response has not been demonstrated. Method-spe-
cific measurement errors could account for differences
in the magnitude of and correlation between office,
h o m e ,a m b u l a t o r yd a y t i m ea n dn i g h t t i m eB Pr e s p o n s e s
[8]. However, an additional possibility is that different
BP response signals are measured by the different
methods.
Since different BP response signals may have different
predictors, our first objective in the present study was
to test the “same signal” model by determining whether
known predictors of BP response, i.e., race, age, and
plasma renin activity, depend on the method of BP mea-
surement. We analyzed data from the Pharmacogenomic
Evaluation of Antihypertensive Responses (PEAR) study,
in which BP responses to single-drug therapy with ate-
nolol or hydrochlorothiazide were measured by all four
methods [7,8]. In this context, our second objective was
to estimate signal-to-noise ratios and compare the
power to identify a genetic polymorphism predicting BP
response when measured by each method separately and
by weighted averages of multiple methods.
Methods
Participants
The PEAR study [17]http://clinicaltrials.gov/ct2/show/
NCT00246519 was approved by the Institutional Review
Board at each site, and all participants gave informed
consent. At an initial consent and screening visit,
trained study personnel administered standardized ques-
tionnaires, performed a limited physical examination,
and obtained blood and urine samples for testing to
establish eligibility for participation [11]. Participants
were provided an automated sphygmomanometer
(MicroLife 3 AC1-PC, Minneapolis MN), the adequacy
of which has been previously validated [18], and with-
drawn from previous antihypertensive drug therapy. The
device was set to measure BP in triplicate with each
activation and to store the average systolic and diastolic
BPs and the time of each set of measurements. Partici-
pants were instructed to take readings daily in the
seated position, one set of three readings in the morning
upon arising from bed and a second set in the evening
just before retiring. At subsequent study visits (prior to
randomization and at the end of therapy), an additional
set of three readings was obtained seated (> 5 minutes)
in the office using the home monitor. In addition, 24-
hour ambulatory BP recordings were obtained at these
visits using Spacelabs (Redmond WA) ambulatory moni-
tors, model 90207, the adequacy of which has been pre-
viously validated [19]. Participants were instructed to
conduct their usual daily activities while wearing the
monitor, which was set to record BP four times per
hour during the day (6 AM to 10 PM) and twice per
hour during the night (10 PM to 6 AM). The average (±
standard deviation) number of ambulatory measure-
ments was 67 ± 10 during daytime hours and 15 ± 3
during nighttime hours.
A tt h ee n do ft h ed r u g - f r e ew a s h o u tp e r i o d ,f a s t i n g
blood samples were drawn in the seated position after
ambulation for measurement of plasma renin activity
[ 1 1 ] .T oq u a l i f yf o rr a n d o m ization, the average home
diastolic BP in the previous week had to be ≥85 mmHg
(consisting of at least five morning and five evening sets
of readings) and the average office diastolic BP ≥ 90
mmHg. Participants received either atenolol or hydro-
chlorothiazide, starting at 50 mg or 12.5 mg daily,
respectively, for two weeks, after which, if BP remained
> 120/70 mmHg, the doses were increased to 100 mg or
25 mg daily, respectively, for six additional weeks.
Statistical analysis
Analyses were performed with Statistical Analysis Sys-
tem software, version 9.1 (SAS, Raleigh-Durham NC).
Statistical significance was defined a priori by P <0 . 0 5 .
The BP response to each drug was calculated for each
measurement method by subtracting the pretreatment
average from the post-treatment average. The home BP
averages consisted of at least five of seven morning and
evening sets of three readings taken during the week
prior to the pre- and post-treatment study visits (i.e., at
least 30 and up to 42 measurements prior to each visit).
Multiple-variable linear regression analyses were per-
formed to identify participant characteristics that made
additive, statistically independent contributions to the
prediction of systolic and diastolic BP response to each
drug. In preliminary analyses, we found that higher pre-
treatment BP level was associated with greater BP
response, as expected [20]. Because we sought to evalu-
ate predictors that are independent of the pretreatment
BP level, we first regressed out the effects of pretreat-
ment BP level and then modeled the effects of other
known predictors of BP response [10,11] as well as
other variables measured at the consent and screening
visit [11,17]. Final multiple-variable models were derived
using a backward stepwise elimination procedure,
retaining only the predictors of both systolic and diasto-
lic BP responses to either drug. In the initial models
that included race and pretreatment plasma renin
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of BP responses and was not retained in the final
models.
To determine whether known predictors of BP
response depend on the method of measuring BP
response, we compared models in which regression
coefficients were constrained to be identical among
measurement methods or allowed to differ among meth-
ods by including interactions of each predictor with the
method of BP measurement. Considering the model in
which the regression coefficients were identical across
methods as a null hypothesis, we attempted to detect
any departures indicating dependency of the predictors
on method of BP measurement that would lead us to
reject the “same signal” model. This analysis used PROC
GENMOD in SAS, which adjusts for the correlation
among the four BP response measurements within each
participant.
To estimate signal-to-noise ratios, the covariance
matrix of the four measured BP responses was used to
estimate the signal and noise components for each
method of measuring BP response after regressing out
the method-specific effects of pretreatment BP level.
The correlation coefficient between BP responses mea-
sured by two methods provides a dimensionless measure
of how much the two responses covary (change
together); the covariance between them expresses the
correlation in units of the two BP responses multiplied
together (mm
2Hg) and is the variance shared between
them, i.e., the signal variance. Since each pair-wise cov-
ariance provides an unbiased estimate of the signal var-
iance, we used the average of the six pairwise
covariances as the BP response signal. Subtracting the
signal from the method-specific total variance provided
an estimate of the method-specific error variance or
noise.
We examined implications of the signal-to-noise ana-
lyses for accomplishing the goal of the PEAR and other
pharmacogenomic studies. Specifically, we compared
power and samples sizes required to identify a genetic
polymorphism that predicts BP response when measured
by each method separately and by weighted averages of
the responses measured by multiple methods. The ratio-
nale for the weighted averages was to increase the signal-
to-noise ratio (and power) by minimizing the error var-
iance. Two different combinations of the measured BP
responses were considered: a weighted average of all four
methods and a weighted average of the office and home
BP responses. The weighted average combinations were
determined based on the row sums of the inverse of the
inter-method covariance matrices, which provide weights
that minimize the variance [21].
For the power and samples size calculations, we
a s s u m e dt h a tag e n e t i cp o l y m o r p h i s mw i t ham i n o r
allele frequency of 0.2 influences the BP response signal
with an effect size that can be detected with 80% power
in a sample of N = 300 at a genome-wide significance
l e v e lo f5×1 0
-8.T h i sP-value was originally suggested
for genome-wide association analysis of 1 million single
nucleotide polymorphisms using a Bonferroni correction
for multiple testing [22]. Based on the estimated signal
variances, we calculated the allele effect sizes (in
mmHg/allele) and the percentage of variation in the BP
response (R
2×100%) explained by the polymorphism.
We then calculated the power to detect the polymorph-
ism in a sample of N = 300 when the BP response is
measured by each method separately and weighted
averages of multiple methods, and the corresponding
sample sizes required to maintain 80% power.
Results
Sample description
Five hundred and ninety-five study participants had
complete measurements of office, home, and ambulatory
daytime and nighttime BP responses (Table 1). Of these,
293 participants were randomized to atenolol (49%) and
302 to hydrochlorothiazide (51%) treatment. Mean
values and relative frequencies of participant characteris-
tics measured prior to randomization did not differ sig-
nificantly between the atenolol and hydrochlorothiazide-
treated groups [11] (not shown).
Office, home, and ambulatory BP response
Means and standard deviations of the systolic and dia-
stolic BP responses differed among measurement meth-
ods (Table 2). For systolic BP response, office
measurements had the greatest mean declines and home
measurements the smallest mean declines in response to
each drug (Table 2). For diastolic BP response, office
measurements also had the greatest mean declines in
response to each drug; ambulatory nighttime measure-
ments had the smallest mean decline in response to ate-
nolol and home measurements the smallest mean
decline in response to hydrochlorothiazide. Correlation
coefficients between the office, home, ambulatory day-
time and nighttime BP responses were modest in magni-
tude (not shown), ranging from 0.36 to 0.71 after
adjustment for differences in pretreatment BP levels (all
P < 0.0001).
The BP response signal and its predictors
We assessed whether the office, home, and ambulatory
daytime and nighttime BP responses measure the same
BP response signal by determining whether the predic-
tors of BP response depend on the method of BP mea-
surement (see Methods). After adjustment for
pretreatment BP level, none of the predictors of BP
response depended upon of the method of BP
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of measuring BP response, the identified predictors
included race, plasma renin activity, and sex (Table 3).
As expected, black race was associated with lesser systo-
lic and diastolic BP responses to atenolol and greater
responses to hydrochlorothiazide; and greater log renin
was associated with greater systolic and diastolic BP
responses to atenolol and lesser responses to hydro-
chlorothiazide [11]. Male sex was independently asso-
ciated with lesser systolic and diastolic BP responses to
each drug. Greater log hypertension years and greater
serum ALT were each independently associated with
greater systolic and diastolic BP responses to atenolol
but not to hydrochlorothiazide.
Signal-to noise-ratios
Inferring that all four methods measure the same BP
response signal, we estimated the signal variance (see
Methods) and calculated the method-specific error var-
iance (noise) and signal-to-noise ratio for each measured
BP response (Figures 1 and 2). The home and ambulatory
daytime BP responses had the largest signal-to-noise ratios
and the ambulatory nighttime and office BP responses the
smallest signal-to-noise ratios (Figure 2). The signal-to-
noise ratios of the home and ambulatory daytime BP
responses were similar in magnitude and up to 4-fold
greater than the signal-to-noise ratios of the office and
ambulatory nighttime BP responses, which were mostly
less than 1 (more noise than signal). Weighted averages of
Table 1 Descriptive characteristics of study participants
Mean ± standard deviation or N (%)
N (%) 595 (100)
Randomized to hydrochlorothiazide, N (%) 302 (51)
Age, years 49.3 ± 9.1
Male, N (%) 280 (47)
Black, N (%) 245 (41)
BMI, kg·m
-2 30.6 ± 5.6
Hypertension duration, years 7.1 ± 7.2
Antihypertensive medication, N (%) 492 (91)
Current smoker, N (%) 69 (13)
Glucose, mg·dL
-1 94.8 ± 10.5
Creatinine, mg·dL
-1 0.9 ± 0.2
Serum ALT, U·L
-1 29.1 ± 15.9
Plasma renin activity, ng·mL
-1·hr
-1 1.0 ± 1.2
Resting heart rate, beat·min
-1 71.0 ± 10.2
Screening office systolic BP, mmHg 137.9 ± 13.8
Screening office diastolic BP, mmHg 89.5 ± 8.8
Pretreatment systolic blood pressure, mmHg 151.5 ± 13.8
Pretreatment diastolic blood pressure, mmHg 98.2 ± 6.3
BMI, body mass index; ALT, alanine aminotransferase; BP, mmHg. Characteristics were measured at the screening visit except pretreatment systolic and diastolic
BP and plasma renin activity were measured at the end of the drug-free washout period prior to initiating atenolol or hydrochlorothiazide therapy.
Table 2 Blood Pressure Responses to Monotherapy by Measurement Method
All N = 595 Atenolol N = 293 Hydrochlorothiazide N = 302
Systolic BP Response, mmHg
Office -13.4 ± 14.7 -13.5 ± 15.6 -13.2 ± 13.7
Home -8.8 ± 9.8 -8.3 ± 10.4 -9.4 ± 9.1
Ambulatory daytime -11.5 ± 10.5 -12.2 ± 11.1 -10.8 ± 9.8
Ambulatory nighttime -9.7 ± 12.5 -8.9 ± 12.9 -10.6 ± 12.1
Contrast P value < 0.001 < 0.001 < 0.001
Diastolic BP Response, mmHg
Office -8.6 ± 8.9 -10.5 ± 9.4 -6.8 ± 7.9
Home -6.6 ± 6.5 -7.8 ± 6.8 -5.3 ± 6.0
Ambulatory daytime -7.6 ± 7.6 -9.2 ± 7.9 -6.1 ± 7.0
Ambulatory nighttime -6.8 ± 9.5 -7.0 ± 10.0 -6.5 ± 9.0
Contrast P value < 0.001 < 0.001 0.10
BP, blood pressure.
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n o i s er a t i o su pt o4 - f o l dc o m p a r e dt ot h eh o m eB P
responses and up to 19-fold compared to the office BP
responses. Weighted averages of the home and office BP
responses improved the signal-to-noise ratios modestly
compared to the home BP responses (by 24% at most).
The weightings, provided in Additional file 1: Table S1,
minimized the error variance (noise) of the average BP
responses (see Methods), thereby accounting for the
improvement in signal-to-noise ratios.
Power and sample size needed to identify a genetic
predictor of blood pressure response
We assumed that a genetic polymorphism with minor
allele frequency of 0.2 influences the BP response signal
and is detected with 80% power at genome-wide signifi-
cance level of 5 × 10
-8 (see Methods) [22]. The T-statis-
tic for association of the polymorphism with BP
response is 6.29; 11.6% of the signal variation is
explained (R
2×100%); and the corresponding effect sizes
(b-coefficients) in mm Hg per allele are 5.22/3.36 for
the systolic/diastolic BP responses to atenolol and 4.04/
2.63 for the systolic/diastolic BP responses to hydro-
chlorothiazide. Based on the signal and noise analyses,
power to detect this polymorphism in a sample size of
N = 300 declined for all methods of measuring BP
response when compared to a perfect method capable
of measuring only signal and no noise (Table 4). Power
declined most markedly for the office BP responses (to
< 5% power) and was only maintained at > 50% for the
Table 3 Multi-variable linear regression modeling of predictors of blood pressure response signal after adjustment for
pretreatment blood pressure level
BP Response to Atenolol (N = 293) BP Response to Hydrochlorothiazide (N = 302)
Systolic b ± SE Diastolic b ± SE Systolic b ± SE Diastolic b ±S E
Intercept -14.1 ± 0.9§ -11.8 ± 0.6§ -11.8 ± 0.7§ -6.7 ± 0.5§
Race: Black 6.3 ± 1.1§ 4.8 ± 0.8§ -2.9 ± 0.9‡ -2.0 ± 0.6‡
Log Plasma Renin Activity -4.4 ± 0.5§ -2.5 ± 0.3§ 0.7 ± 0.5 0.7 ± 0.3*
Sex: Male 2.3 ± 1.0* 2.9 ± 0.7§ 4.2 ± 0.8§ 2.7 ± 0.5§
Log Hypertension Years 1.3 ± 0.5* 1.0 ± 0.4† --
Serum ALT 0.08 ± 0.03† 0.04 ± 0.02* - -
Model R
2×100% 22% 23% 11% 16%
BP, blood pressure; b, regression coefficient; SE, standard error. Model parameters are estimated at the mean values for each quantitative predictor variable in a
combined dataset used to model the predictors of office, home, ambulatory daytime and nighttime BP responses after adjustment for pretreatment BP levels. P-
values for tests of model parameters = 0: *, ≤0.05; †, ≤0.01; ‡, ≤ 0.001; §, ≤0.0001. R
2×100% is the percentage of variation in the office BP response explained by
the model predictors.
Figure 1 Signal, noise, and total variances of the measured blood pressure responses to single-drug therapy with atenolol or
hydrochlorothiazide and their weighted averages.
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maintain 80% power the sample sizes would need to be
increased for all methods of measuring BP response
when compared to the N = 300 sample size for the per-
fect measurement of signal without noise (Table 4). The
s a m p l es i z e si n c r e a s e dm o s tm a r k e d l yf o rt h eo f f i c eB P
responses (by > 200%), but only modestly for the
weighted averages of all four methods (by ≤ 26%).
Discussion
Our first objective was to assess whether office, home,
and ambulatory daytime and nighttime measurements of
Figure 2 Signal-to-noise ratios of the measured blood pressure responses to single-drug therapy with atenolol or hydrochlorothiazide
and their weighted averages.
Table 4 Power and sample sizes to detect single nucleotide polymorphism influencing BP response measured by
office, home, ambulatory daytime and nighttime blood pressure
Drug
Atenolol Hydrochlorothiazide
Power, N = 300 N, 80% power Power, N = 300 N, 80% power
Systolic BP response signal 80% 300 80% 300
Measurement methods
Office 4% 780 1.5% 1013
Home 42% 416 24% 500
Ambulatory day 41% 420 18% 540
Ambulatory night 17% 552 12% 607
Weighted averages
All methods 70% 328 61% 353
Home and office 45% 404 30% 467
Diastolic BP response signal 80% 300 80% 300
Measurement methods
Office 5% 764 3% 884
Home 39% 426 19% 537
Ambulatory day 39% 426 19% 537
Ambulatory night 27% 484 7% 695
Weighted averages
All methods 63% 348 379
Home and office 42% 416 26% 489
BP, blood pressure. The power and sample size estimates are for a single nucleotide polymorphism with minor allele frequency of 0.2 that influences theB P
response signal with an effect size detected with 80% power in a sample of N = 300 at a genome-wide significance level of 5 × 10
-8(see Methods). The estimates
assume that the BP response signal can be measured without error.
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BP response signal. Since different BP response signals
may have different predictors, this assessment was based
on determining whether known predictors of BP
response [11] depend on the method of BP measure-
ment. After adjustment for the method-specific effects
of pretreatment BP level, the identified predictors of BP
response were independent of the method of BP mea-
surement. This finding supports the inference that
office, home, and ambulatory daytime and nighttime BP
responses measure the same BP response signal.
Our second objective was to estimate signal-to-noise
ratios and compare the power to identify a genetic poly-
morphism predicting BP response when measured by
each method separately and by weighted averages of
multiple methods. Estimation of the BP response signal
allowed us to also compare each method with a theore-
tically perfect measurement consisting of pure signal
and no noise. We reasoned that greater signal-to-noise
ratios would translate into greater power and smaller
sample sizes required to identify a polymorphism influ-
encing BP response to antihypertensive drug therapy.
Not surprisingly, signal-to-noise ratios were greater for
the home and ambulatory daytime methods, which are
based on more measurements per subject and have
smaller error variances, than for the office and ambula-
tory nighttime methods, which are based on fewer mea-
surements per subject and have larger error variances.
Particularly unsettling were the signal-to-noise ratios
less than one for office and ambulatory nighttime BP
responses, indicating more noise than signal for these
methods. Such measurement imprecision could account
for limited success in previous studies to identify predic-
tors of office BP response [12,23] and the requirement
for sample sizes in the tens of thousands for genome-
wide association analyses of BP level [24]. Moreover, the
profound lack of power to identify a genetic predictor of
BP response in sample sizes ≤300, and the large
increases in sample size required to maintain 80%
power, emphasizes the need for more precise methods
of measuring BP response than office BP measurements
provide [25].
Although the home and ambulatory daytime BP
responses provided greater power than the office and
ambulatory nighttime BP responses, the estimated sam-
ple size required to maintain 80% power with either
method was still in excess of the number of participants
randomized to each single-drug therapy in the PEAR
study (i.e., N = 400). Consequently, we pursued addi-
tional strategies to increase power by combining all of
the measurements from multiple methods in a weighted
average, with the weights chosen to minimize the error
variance (noise) and maximize the signal-to-noise ratio
of the resulting average. We provided two examples: a
weighted average of measurements from all four meth-
ods and a weighted average of the home and office mea-
surements. The latter uses the two most feasible and
widely available methods of measuring antihypertensive
drug responses. While both weighted averages demon-
strated improvements in the signal-to-noise ratios rela-
tive to the separate methods of measuring BP response,
only with the weighted average of all four methods was
power maintained at 80% without an increase in sample
size exceeding the N = 400 randomized to each single-
drug therapy in the PEAR study. These signal and noise
analyses, power calculations, and sample size estimates
based on the PEAR study emphasize the “make-or-
break” contribution that precision in measurement of
the phenotype can make to success of genome-wide
association studies [26].
Given our interest in the PEAR study to identify new
predictors of BP response, several additional results of
our analyses are noteworthy. First, although signal var-
iances were greater for the systolic than the diastolic BP
responses, the error variances were also greater and the
signal-to-noise ratios differed little between the systolic
and diastolic BP responses. This finding suggests that
neither phenotype affords greater opportunity than the
other to identify its predictors. This suggestion is sup-
ported by the finding that each known predictor was a
statistically significant predictor of both systolic and dia-
stolic BP responses (Table 3). Second, greater signal and
signal-to-noise ratios for the BP responses to atenolol
might suggest greater predictability of BP response to
atenolol than to hydrochlorothiazide. This suggestion is
supported by the finding that two identified predictors
of BP response to atenolol were not predictors of BP
response to hydrochlorothiazide (Table 3). Third, male
sex was associated with lesser systolic and diastolic BP
responses to both atenolol and hydrochlorothiazide in
this study and to hydrochlorothiazide in a previous
pharmacogenetic study [12]. Male sex was also pre-
viously associated with lesser responses to quinapril [27]
and candesartan [13]. To our knowledge, this apparently
consistent association of male sex with lesser BP
response to drugs from different pharmacological classes
has not been previously recognized.
Despite many studies of antihypertensive drugs con-
ducted since the 1950s, few patient characteristics have
been identified that predict inter-individual differences
in BP responses. Methods that reduce the error in mea-
suring blood pressure response, especially weighted
averages of the responses measured by multiple meth-
ods, improve signal-to-noise ratios and provide greater
power to identify the predictors of response in smaller
sample sizes. Their incorporation in the design of phar-
macogenomic studies such as the PEAR study will be
critical to success in identifying novel genetic
Turner et al. Journal of Translational Medicine 2012, 10:47
http://www.translational-medicine.com/content/10/1/47
Page 7 of 9polymorphisms that improve the ability to predict BP
response to antihypertensive drug therapy.
Conclusion
Since different methods of measuring BP response to
antihypertensive drug therapy measure the same signal,
weighted averages of the BP responses measured by
multiple methods minimize measurement error and
optimize power to identify genetic predictors of BP
response.
Additional material
Additional file 1: Additional file 1: Table S1. Esimated weights for
calculation of minimum variance weighted average blood pressure
responses.
Acknowledgements
We gratefully acknowledge the valuable contributions of the study
participants, support staff, and study physicians: Drs. George Baramidze, R.
Whit Curry, Karen Hall, Karen Hall, Frederic Rabari-Oskoui, Dan Rubin, and
Siegfried Schmidt. In addition, we gratefully acknowledge the biostatistical
analyses of Daniel Crusan. Funding was from NIH Pharmacogenetics
Research Network grant U01-GM074492; K23 grants HL091120 (A. L.
Beitelshees) and HL086558 (R. M. Cooper-DeHoff); CTSA grants UL1-
RR092890 (University of Florida), UL1-RR025008 (Emory University), and UL1-
RR024150 (Mayo Clinic); and funds from the Mayo Foundation.
Author details
1Division of Nephrology and Hypertension, Department of Medicine, Mayo
Clinic, Rochester, MN 55905, USA.
2Division of Biostatistics, Department of
Health Sciences Research, Mayo Clinic, 200 First Street S.W, Rochester, MN,
USA.
3Renal Division, Department of Medicine, Emory University School of
Medicine, Atlanta, Georgia, USA.
4Department of Medicine, University of
Maryland School of Medicine, Baltimore, MD, USA.
5Department of
Pharmacotherapy and Translational Research and Center for
Pharmacogenomics, University of Florida, Gainesville, FL, USA.
6Department
of Community Health and Family Medicine, University of Florida, Gainesville,
FL, USA.
7Department of Medicine, University of Florida, Gainesville, FL, USA.
8Human Genetics and Institute of Molecular Medicine, University of Texas
Health Science Center, Houston, TX, USA.
Authors’ contributions
ST and GS participated in the design of the study, collected and analyzed
the data, and drafted and revised the manuscript. AB, JG, RCD participated
in the design of the study, collected the data and participated in revision of
the manuscript. JJ conceived and designed the study, collected the data,
and participated in revision of the manuscript. EB participated in design of
the study and revision of the manuscript. KB participated in design of the
study, analyzed the data, and participated in drafting and revision of the
manuscript. All authors read and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 20 December 2011 Accepted: 13 March 2012
Published: 13 March 2012
References
1. Parati G, Omboni S, Bilo G: Why Is Out-of-Office Blood Pressure
Measurement Needed? Home Blood Pressure Measurements Will
Increasingly Replace Ambulatory Blood Pressure Monitoring in the
Diagnosis and Management of Hypertension. Hypertension 2009,
54:181-187.
2. Appel LJ, Stason WB: Ambulatory blood pressure monitoring and blood
pressure self-measurement in the diagnosis and management of
hypertension. Ann Intern Med 1993, 118:867-882.
3. Mancia G, Parati G: Ambulatory blood pressure monitoring and organ
damage. Hypertension 2000, 36:894-900.
4. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J,
Mallion JM: Cardiovascular prognosis of “masked hypertension” detected
by blood pressure self-measurement in elderly treated hypertensive
patients. JAMA 2004, 291:1342-1349.
5. Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G,
O’Brien ET: Antihypertensive treatment based on blood pressure
measurement at home or in the physician’s office: a randomized
controlled trial. JAMA 2004, 291:955-964.
6. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW,
Mancia G, Nachev C, Palatini P, Parati G, et al: Predicting cardiovascular
risk using conventional vs ambulatory blood pressure in older patients
with systolic hypertension. Systolic Hypertension in Europe Trial
Investigators [see comments]. JAMA 1999, 282:539-546.
7. Mancia G, Parati G: Office compared with ambulatory blood pressure in
assessing response to antihypertensive treatment: a meta-analysis. J
Hypertens 2004, 22:435-445.
8. Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG: Changes in
home versus clinic blood pressure with antihypertensive treatments: a
meta-analysis. Hypertension 2008, 52:856-864.
9. Turner ST, Schwartz GL, Boerwinkle E: Personalized medicine for high
blood pressure. Hypertension 2007, 50:1-5.
10. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ,
Cushman WC, Anderson RJ: Age-race subgroup compared with renin
profile as predictors of blood pressure response to antihypertensive
therapy. Department of Veterans Affairs Cooperative Study Group on
Antihypertensive Agents. JAMA 1998, 280:1168-1172.
11. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-
DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR: Plasma renin activity
predicts blood pressure responses to beta-blocker and thiazide diuretic
as monotherapy and add-on therapy for hypertension. Am J Hypertens
2010, 23:1014-1022.
12. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST: Predictors of
antihypertensive response to a standard dose of hydrochlorothiazide for
essential hypertension. Kidney Int 2002, 61:1047-1055.
13. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E,
Turner ST, Chapman AB: Predictors of blood pressure response to the
angiotensin receptor blocker candesartan in essential hypertension. Am
J Hypertens 2008, 21:61-66.
14. Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST:
Reproducibility of blood pressure response to hydrochlorothiazide. J Clin
Hypertens (Greenwich) 2002, 4:408-412.
15. Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST: Lack of
agreement between office and ambulatory blood pressure responses to
hydrochlorothiazide. Am J Hypertens 2005, 18:398-402.
16. Beitelshees AL, Gong Y, Bailey KR, Turner ST, Chapman AB, Schwartz GL,
Gums JG, Boerwinkle E, Johnson JA: Comparison of office, ambulatory,
and home blood pressure antihypertensive response to atenolol and
hydrochlorthiazide. J Clin Hypertens (Greenwich) 2010, 12:14-21.
17. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-
DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, et al:
Pharmacogenomics of antihypertensive drugs: rationale and design of
the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
study. Am Heart J 2009, 157:442-449.
18. Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG:
Validation of two devices for self-measurement of brachial blood
pressure according to the International Protocol of the European Society
of Hypertension: the SEINEX SE-9400 and the Microlife BP 3AC1-1. Blood
Press Monit 2005, 10:325-331.
19. O’Brien E, Mee F, Atkins N, O’Malley K: Accuracy of the SpaceLabs 90207
determined by the British Hypertension Society protocol. J Hypertens
1991, 9:573-574.
20. Gill JS, Zezulka AV, Beevers DG, Davies P: Relation between initial blood
pressure and its fall with treatment. Lancet 1985, 1:567-569.
21. Snedecor GW, Cochran WG: Statistical methods. 7 edition. Ames IA,: Iowa
State Univ. Press; 1980.
Turner et al. Journal of Translational Medicine 2012, 10:47
http://www.translational-medicine.com/content/10/1/47
Page 8 of 922. Risch N, Merikangas K: The future of genetic studies of complex human
diseases. Science 1996, 273:1516-1517.
23. Cannella G, Paoletti E, Barocci S, Massarino F, Delfino R, Ravera G, Di
Maio G, Nocera A, Patrone P, Rolla D: Angiotensin-converting enzyme
gene polymorphism and reversibility of uremic left ventricular
hypertrophy following long-term antihypertensive therapy. Kidney Int
1998, 54:618-626.
24. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL,
Morrison AC, Johnson AD, Aspelund T, et al: Genome-wide association
study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
25. Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, Remme WJ,
Asselbergs FW, van Gilst WH, Macmahon S, et al: Monitoring initial
response to Angiotensin-converting enzyme inhibitor-based regimens:
an individual patient data meta-analysis from randomized, placebo-
controlled trials. Hypertension 2010, 56:533-539.
26. Macrae CA, Vasan RS: Next-generation genome-wide association studies:
time to focus on phenotype? Circ Cardiovasc Genet 2011, 4:334-336.
27. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, Dudley A,
Flack JM: Determinants of blood pressure response to quinapril in black
and white hypertensive patients: the Quinapril Titration Interval
Management Evaluation trial. Hypertension 2004, 43:1202-1207.
doi:10.1186/1479-5876-10-47
Cite this article as: Turner et al.: Power to identify a genetic predictor of
antihypertensive drug response using different methods to measure
blood pressure response. Journal of Translational Medicine 2012 10:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Turner et al. Journal of Translational Medicine 2012, 10:47
http://www.translational-medicine.com/content/10/1/47
Page 9 of 9